Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

9.10USD
23 Feb 2018
Change (% chg)

$0.70 (+8.33%)
Prev Close
$8.40
Open
$8.50
Day's High
$9.10
Day's Low
$8.50
Volume
440,807
Avg. Vol
388,295
52-wk High
$9.50
52-wk Low
$1.50

Chart for

About

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications,... (more)

Overall

Beta: 1.82
Market Cap(Mil.): $721.83
Shares Outstanding(Mil.): 79.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001

* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY

Jan 29 2018

BRIEF-Henry Ji Reports 5.9 Pct Passive Stake In Sorrento Therapeutics

* HENRY JI REPORTS 5.9 PERCENT PASSIVE STAKE IN SORRENTO THERAPEUTICS INC AS OF JANUARY 21, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2netHja) Further company coverage:

Jan 26 2018

BRIEF-Sorrento Therapeutics Enteres Into Securities Purchase Agreement

* SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING

Dec 11 2017

BRIEF-Sorrento Therapeutics files for mixed shelf of upto $350 mln

* Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​ Source text: [http://bit.ly/2yLg1nW] Further company coverage:

Nov 09 2017

BRIEF-Sorrento Therapeutics- ‍Terminated​ deal with Semnur Pharma to purchase all its issued and outstanding equity

* Sorrento Therapeutics - ‍ co, unit Semnur Pharmaceuticals terminated​ deal by which unit would, purchase all of issued and outstanding equity of Semnur Source text: (http://bit.ly/2xYZewg) Further company coverage:

Oct 06 2017

BRIEF-Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​

* Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​ Source text: (http://bit.ly/2xTIxlX) Further company coverage:

Oct 05 2017

BRIEF-FDA acknowledges receipt of Sorrento Therapeutics Inc's NDA for Ztlido

* Fda acknowledges receipt of Sorrento Therapeutics Inc, NDA for Ztlido; PDUFA date set for February 28, 2018

Sep 12 2017

BRIEF-Sorrento Therapeutics submits NDA for Ztlido

* Sorrento Therapeutics Inc submits NDA for Ztlido next-generation lidocaine patch

Aug 29 2017

Competitors

Earnings vs. Estimates